Interleukin-21 (IL-21) has been recently shown to modulate the growth of specific types of B-cell neoplasm. Here, we studied the biological effects of IL-21 in mantle cell lymphoma (MCL). All MCL cell lines and tumors examined expressed the IL-21 receptor. Addition of recombinant IL-21 (rIL-21) in vitro effectively induced STAT1 activation and apoptosis in MCL cells. As STAT1 is known to have tumor-suppressor functions, we hypothesized that STAT1 is important in mediating IL-21-induced apoptosis in MCL cells. In support of this hypothesis, inhibition of STAT1 expression using siRNA significantly decreased the apoptotic responses induced by IL-21. To further investigate the mechanism of IL-21-mediated apoptosis, we employed oligonucleotide arrays to evaluate changes in the expression of apoptosis-related genes induced by rIL-21; rIL-21 significantly upregulated three proapoptotic proteins (BIK, NIP3 and HARAKIRI) and downregulated two antiapoptotic proteins (BCL-2 and BCL-XL/S) as well as tumor necrosis factor-a. Using an ELISA-based assay, we demonstrated that rIL-21 significantly decreased the DNA binding of nuclear factor-jB, a transcriptional factor known to be a survival signal for MCL cells. To conclude, IL-21 can effectively induce apoptosis in MCL via a STAT1-dependent pathway. Further understanding of IL-21-mediated apoptosis in MCL may be useful in designing novel therapeutic approaches for this disease.
Introduction
Mantle cell lymphoma (MCL) is a distinct type of B-cell nonHodgkin's lymphoma defined by a constellation of pathologic, cytogenetic and clinical features. 1 One of the characteristic features of MCL is the recurrent chromosomal translocation, t(11;14)(q13;q32), which brings the cyclin D1 gene under the control of the enhancer of the immunoglobulin heavy chain gene (IgH), leading to overexpression of the cyclin D1 protein.
Although it is widely accepted that cyclin D1 plays an important role in the pathogenesis of MCL, accumulating evidence suggests that MCL often has defects in many other cellular processes, such as those involved in cell-cycle regulation, apoptosis and DNA repair. 2, 3 With regard to apoptosis, MCL is well known to be resistant to apoptosis induced by a variety of conventional chemotherapeutic agents. 2 Recent studies have revealed a number of biochemical defects which may contribute to its relatively high resistance to apoptosis, including constitutive activation of the nuclear factor (NF)-kB pathway, overexpression of several antiapoptotic proteins and the absence of Fas receptor. [4] [5] [6] [7] [8] [9] Aberrant cellular signaling such as the PI3K/Akt pathway may also contribute to the chemoresistance of MCL. [10] [11] [12] [13] Despite the advent of several new therapeutic agents, 14 a significant proportion of MCL patients fails to show a significant improvement in the clinical outcome. 2 Thus, there is a need to continue to develop new therapeutic strategies for this disease.
Interleukin-21 (IL-21), produced by Th17T cells, is a recently discovered member of the IL-2 cytokine family. 15 As an IL-2 family member, IL-21 triggers cellular signaling by binding to its specific receptor (that is, IL-21R) that is coupled with the common g c chain. Following activation and tyrosine phosphorylation of JAK1 and JAK3, both STAT1 and STAT3 are known to be activated and phosphorylated in various cell types. [16] [17] [18] [19] IL-21 has been shown to mediate a range of biological effects in B cells. For instance, IL-21 induces apoptosis in murine B cells. 20 In contrast, IL-21 has been reported to promote cell proliferation in human B cells. 21 In human B-cell neoplasms, IL-21 has been recently shown to induce apoptosis in chronic lymphocytic leukemia and follicular lymphoma. [22] [23] [24] Paradoxically, in plasma cell myeloma, IL-21 induces cell proliferation rather than apoptosis. 25 Thus, the biological effects of IL-21 in benign and neoplastic B cells may be dependent on the stage of differentiation and/or activation status.
The biological effects of IL-21 in MCL have never been investigated. In this study, we aimed to characterize the biological effects of IL-21 in MCL. For the first time, we demonstrated that IL-21 can effectively induce apoptosis in MCL. We have also investigated the mechanism underlying this apoptotic response to IL-21, and our results highlight the importance of STAT1 in this setting.
Materials and methods

Cell culture and treatment
Three previously described MCL cell lines, Mino, SP53 and Rec-1, were used in this study. 26, 27 Briefly, they express cyclin D1 and carry an mature B-cell immunophenotype as well as the t(11;14)(q13; q32) cytogenetic abnormality. All of these three cell lines are negative for the Epstein-Barr virus nuclear antigen. At the beginning of each experiment, exponentially growing cells were suspended in the culture medium (RPMI 1640 supplemented with glutamine and 10% fetal bovine serum) at a density of 5 Â 10 4 cells/ml. Cells were treated with human recombinant IL-21 (rIL-21) purchased from Invitrogen (Burlington, Ontario, Canada). Cell counts and viability were determined by using trypan blue exclusion (Sigma-Aldrich, St Louis, MO, USA) and a hemocytometer. Cell growth was also assessed using the MTS assay (Promega, Madison, WI, USA).
Immunofluorescence staining and confocal microscopy
Immunofluorescence was performed using standard techniques. Briefly, cells were grown on coverslips placed in a six-well plate and fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS; pH ¼ 7.5). Cells were then rinsed with PBS, permeabilized with PBS-0.5% triton X-100 for 5 min, and rinsed twice with PBS. Subsequently, cells were incubated with 200 ml of an anti-IL-21R antibody (Sigma-Aldrich) overnight at 4 1C followed by three washings with PBS. Cells were then incubated with 200 ml of Alexa 499 goat anti-rabbit secondary antibody for 60 min. After washing with PBS and the addition of a mounting medium (Dako, Mississauga, Ontario, Canada), cells were visualized with a Zeiss LSM 510 confocal microscope (Oberkochen, Germany) at the Cross Cancer Institute imaging facility. Addition of unconjugated mouse IgG1 (as the isotype control) in place of anti-IL-21R served as a negative control.
Immunoblotting and antibodies
Details of immunoblotting have been previously described. 28 Briefly, cells were washed twice with ice-cold NaCl (150 mmol/ l) and precipitated with 5% trichloroacetic acid overnight at 4 1C. After centrifugation at 15 000 g, proteins were dissolved in a sample buffer, subjected to SDS-polyacrylamide gel electrophoresis, blotted onto nitrocellulose membrane (Amersham Canada, Oakville, ON, Canada). Blocking of nonspecific antibody binding was achieved by incubating the membranes overnight at 4 1C with Tris-buffered saline (pH ¼ 7.5) that was supplemented with 0.1% Tween 20 and 5% nonfat dry milk. Antibodies used in this study included caspase-3, -7, -8 and -9, poly(ADP-ribose) polymerase (PARP) (Cell Signaling, Danvers, MA, USA) and actin (Sigma-Aldrich). With the exception of actin, which was used at a concentration of 1 in 4000, all of the other antibodies were used at a concentration of 1 in 1000.
Reverse transcriptase-polymerase chain reaction
Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to detect IL-21R mRNA. Total RNA was prepared with the Trizol (Invitrogen) in accordance with the manufacturer's suggested protocol. Briefly, cDNA synthesis was carried out for 30 min at 42 1C using the superscript reverse transcriptase (Invitrogen). PCR amplification was performed in a reaction mixture containing 2 ml of cDNA and 2.5 units of TaqDNA polymerase, 2 mM MgCl2, 1 mM dNTP and 100 ng of each primer and PCR buffer (Invitrogen) in a final volume of 50 ml. PCR was run in a thermal cycler (Applied Biosystems, Streetville, Ontario, Canada) for 30 cycles under the following conditions: 94 1C for 1 min, 56 1C for 45 s, 72 1C for 1 min. The following IL-21 primer set primers was used: IL-21R sense -
0 . Amplification of the GAPDH housekeeping gene was used as the internal control, and the primer set was previously published. 28 The PCR products were visualized on a 1.5% agarose gel containing ethidium bromide.
MCL patient tumor samples
Frozen lymph node samples (n ¼ 5) from patients with MCL were retrieved from the file at the Department of Laboratory Medicine and Pathology, Cross Cancer Institute. In addition, to assess the sensitivity of primary MCL cells to rIL-21 in vitro, we collected the peripheral blood mononuclear cells from two patients with leukemic MCL. The use of these tissues was approved by the Institutional Ethics Committee. The diagnosis of these cases was based on the criteria established by the World Health Organization Classification scheme, 1 and all cases were confirmed to express cyclin D1 by immunohistochemistry.
Short interference RNA
Short interference RNA (siRNA) for STAT1 (HSS110272 and HSS110273) and scrambled siRNA (no. 12935-200 and no. 12935-300) were obtained from Invitrogen. For each experiment, 1 Â 10 6 MCL cells were transfected in six-well plates with either STAT1 siRNA or scrambled siRNA using the lipofectamine 2000 reagent (Invitrogen) as per manufacturer's suggested protocol. At 24 h after the transfection, cells were placed in 96-well plates at 5 Â 10 4 cells/ml containing the complete growth medium and treated with or without IL-21, and the number of viable cells and cell growth was assessed using trypan blue exclusion and MTS, respectively, for up to 4 days after transfection.
Analysis of expression of apoptotic genes using oligonucleotide array
We employed the RT 2 Profiler PCR Array Human apoptosis Signaling Pathway array purchased from SuperArray Bioscience Corporation (Frederich, MD, USA). The complete gene list is available on www.superarray.com. Total RNA from Mino cells treated with or without 10 ng/ml of rIL-21 for 2 days were isolated using Trizol (Invitrogen). First-strand cDNA synthesis reaction was performed as follows: 2 mg of extracted RNA was mixed with 10 ml of the SuperArray RT cocktail mix. The products were then incubated at 37 1C for 1 h and heated at 95 1C for 5 min. Quantitative SYBR green PCR was performed IL-21 in mantle cell lymphoma P Gelebart et al using an ABI 7900HT instrument (Applied Biosystems) and the following thermal cycling condition was employed: 95 1C for 10 min, followed by 40 cycles of 95 1C for 15 s and 60 1C for 60 s. The cycle threshold (CT) values, which are defined as the fractional cycle number at which the fluorescence passes an arbitrarily set threshold, were analyzed using the SDS (version 2.2.2) program (Applied Biosystems). The CT value of each gene was normalized to that of GAPDH, which is included in this commercially available kit. Triplicate experiments were performed and the statistical significance of the differences between the rIL-21-treated cells and the negative controls were assessed by Student's t-test.
Assessment of the DNA binding of NF-kB
Extraction of nuclear proteins was performed using a kit from Panomics (Fremont, CA, USA) as per the manufacturer's suggested protocol. Protein quantification was determined by the BCA protein assay kit (Pierce, Rockford, IL, USA). The NF-kB transcription factor ELISA kit from Panomics was used to assess the DNA binding of NF-kB. Briefly, to form the NF-kB/DNA complex, 40 ml of binding buffer master mix was incubated with 10 ml of sample nuclear extract (0.7 mg/ml) in the sample plates for 30 min at room temperature. From each well of the sample plate, 45 ml was then transferred to the assay plate. To capture the NF-kB/DNA complex, the assay plates were washed three times with a provided buffer and the samples were incubated with a primary antibody against NF-kB (in 1:200 dilution) 1 h at room temperature. After washing and incubation with the secondary antibody, the plates were washed three times with the provided washing buffer. Colorimetric signals were then developed by adding a substrate solution, and read by using a Biorad spectrophotometer (Biorad, Hercules, CA, USA) at 450 nm.
Measurement of secreted TNFa in the culture media
Secreted tumor necrosis factor-a (TNFa) in the culture media was measured using an ELISA kit purchased from Cayman Chemical (Ann Arbor, MI, USA). Briefly, after incubating with human rIL-21 at 10 ng/ml for 2 days, MCL cells were centrifuged at 300 g for 10 min, and the cell culture supernatant was stored at À80 1C until use. The ELISA assay was performed in accordance with the manufacturer's suggested protocol. Experiments were performed in triplicate and statistical analysis was performed using Student's t-test.
Measurement of mitochondrial membrane potential
Dissipation of mitochondrial membrane potential (DCm) is one of the key events during apoptosis. 29 Variations of the DCm IL-21 in mantle cell lymphoma P Gelebart et al during apoptosis were studied using 3,3 0 -dihexyloxacarbocyanine iodide, DiOC6(3), purchased from Invitogen. Briefly, 2.5 Â 10 5 MCL cells treated with or without rIL-21 at 20 ng/ml for 2 days were stained for 15 min with 5 nM of DiOC6(3) at 37 1C. After incubation, cells were immediately analyzed using the FACScan (Becton Dickinson Biosciences, San Jose, CA, USA).
Flow cytometric studies of IL-21 receptor expression
MCL cells were fixed in the CytoFix Buffer from Becton Dickinson Biosciences, washed in cold PBS, centrifuged and resuspended in the fluorescein-activated cell scanner (FACS) staining buffer purchased from Becton Dickinson. Cells were incubated with primary antibodies for 60 min at 4 1C in the dark, and washed twice using cold buffer between incubations. The following antibodies were employed: unconjugated mouse IgG 1 as the isotype control (10 mg/ml; Santa Cruz biotechnology, Santa Cruz, CA, USA), unconjugated mouse anti-human IL-21R (IgG1, 10 mg/ml, clone MAB9911, R&D Systems, Minneapolis, MN, USA); phycoerythrin-conjugated rat anti-mouse antibody (IgG1, 5 mg/ml; BD Biosciences, San Jose, CA, USA). FACS analyses were carried out using the FACScan (Becton Dickinson) and accompanying CELLQuest software (San Jose, CA, USA) as per manufacturer's guidelines.
Quantitative reverse transcriptase-polymerase chain reaction
Total cellular RNA was extracted using the TRIzol extraction method (Gibco, Carlsbad, CA, USA) from Mino cells incubated with or without rIL-21 for 2 days at 10 ng/ml. Reverse transcription was performed using 500 ng of total RNA using the superscript reverse transcriptase (Invitrogen). qRT-PCR was performed using the platinum SYBR green qPCR supermix-UDG (Invitrogen) and the primer sets are detailed in Supplementary  Figure 1 . qRT-PCR was performed using the ABI 7900HT instrument and a procedure similar to that described for the oligonucleotide array studies.
Results
MCL consistently expresses the IL-21 receptor
We first determined the expression of IL-21R in three MCL cell lines and five tumors. Using RT-PCR, both MCL cell lines (SP53, Mino) and five patient samples (P1-P5) examined expressed readily detectable levels of the IL-21R transcript (Figure 1a) , which identity was confirmed by sequencing. HepG2 cells were used as a positive control for IL-21R. Using confocal microscopy, we confirmed the protein expression of IL-21R in the two MCL cell lines, and the staining was localized to the cell membrane (Figure 1b) . The IgG isotype control (negative control) showed no staining. We further assessed the expression of IL-21R using flow cytometry. As shown in Supplementary Figure 2 , all three MCL cell lines showed surface expression of IL-21R. Figure 3 , IL-21 at 50 ng/ml also reduced the number of viable cells by approximately 50% on day 3.
rIL-21 significantly reduces cell growth in MCL cells
IL-
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rIL-21 induces apoptosis in MCL
To determine whether the reduction in the cell viability is due to apoptosis, we first assessed if there were any morphologic changes characteristic of apoptosis in MCL cells treated with rIL-21. As illustrated in Figure 3a , Mino cells treated with 20 ng/ml of rIL-21 for 3 days underwent nuclear condensation and fragmentation, both of which are characteristic features of apoptosis. To further investigate if rIL-21 induces apoptosis in MCL, we assessed the expression and cleavage of various caspases involved in the intrinsic or extrinsic apoptotic pathways. Mino cells treated with rIL-21 for 5 days (Figure 3b) showed a substantial increase in the levels of cleaved caspase 3, 7, 8 and 9 and PARP. SP53 cells treated with different (a and b) . To assess the kinetics of STAT1 and STAT3 activation, SP53 were treated with rIL-21 (c), and western blots revealed that pSTAT1, more than pSTAT3, were sustained at 4 and 18 h. The pSTAT1/STAT1 ratio and the pSTAT3/STAT3 ratio, both of which were normalized against a-tubulin and obtained from mantle cell lymphoma (MCL) cells treated by rIL-21 for 4 hours, are illustrated (d). Figure 3c ) also showed a substantial increase in the levels of cleaved caspase 3, 7, 8 and 9 and PARP. Rec-1 cells treated with 50 ng/ml or 75 ng/ml of IL-21 also showed evidence of apoptosis, as there was cleavage of PARP, caspase 3, 7 and 9 (Supplementary Figure 4) . As shown in Figure  3d and e, IL-21 treatment also induced significant changes in the DCm. Lastly, we tested if primary MCL cells are also sensitive to IL-21-induced apoptosis. As shown in Supplementary Figure 5 , both MCL cases showed cleavages of PARP, caspase 3 and 9, on incubation with IL-21 (50 ng/ml) for 3 days.
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rIL-21 induces activation of STAT1 and STAT3 in MCL cells
It has been previously reported that IL-21 exerts its biological effects by activating several STAT family members such as STAT1 and STAT3. 15 Thus, to assess the functionality of the IL-21 signaling pathway in MCL, we examined changes in the activation status of STAT1 and STAT3 in MCL cells treated with rIL-21. As illustrated in Figures 4a and b , both MCL cell lines had undetectable expression of the phosphorylated form of STAT1 (that is, pSTAT1) and STAT3 (that is, pSTAT3) at the steady state. Both of these two cells lines showed a dramatic upregulation of pSTAT1 and pSTAT3 at 30 min after rIL-21 treatment. STAT5, which has been reported to be activated in response to IL-21 in other cell types, 30 was not activated at the steady state for Mino cells, and it did not show any evidence of increased phosphorylation after rIL-21 treatment for both cell lines.
To further assess the kinetics of STAT1 and STAT3 activation induced by rIL-21 in MCL cells, we performed a time-course study and the results are illustrated in Figure 4b and c. Both pSTAT1 and pSTAT3 were detected at 4 and 18 h, although the levels for both phosphoproteins decreased at 18 h. An increase of rIL-21concentration from 50 ng/ml to 100 ng/ml did not appreciably increase the levels of pSTAT1 and pSTAT3 at 4 or 18 h. Overall, activation of STAT1 appeared to be more pronounced than STAT3 activation, as illustrated in Figure 4d in which the pSTAT1/STAT1 ratio was higher than that of pSTAT3/ STAT3. Both ratios had been normalized to the tubulin levels.
rIL-21-induced apoptosis in MCL is STAT1 dependent
In view of the known tumor-suppressor functions of STAT1 and the fact that pSTAT1 was highly activated by rIL-21, we hypothesized that the IL-21-mediated apoptosis in MCL cells might be dependent of STAT1. Mino and SP53 cells were treated with control-scrambled siRNA or with two different STAT1 siRNA at 80 pmol. As shown in Figure 5 , STAT1 siRNA induced a 40-50% reduction in the STAT1 expression level in both cell lines. Further increase in the siRNA dosages did not result in a dramatic further reduction in STAT1. With this experimental system, we tested if a downregulation of STAT1 expression in MCL cells might result in a decrease in the biological response induced by rIL-21. As shown in Figures 6a and b, siRNA downregulation of STAT1 significantly reduced the cell growth inhibitory effects of rIL-21 in both Mino and SP53 cells. The observations that STAT1 siRNA did not completely abrogate the biological effects of rIL-21 is expected, because we were able to only downregulate STAT1 level by approximately 50%.
rIL-21 induces a proapoptotic shift
To further investigate the mechanism by which apoptosis is induced by IL-21 in MCL, we employed the oligonucleotide arrays specifically designed to assess the apoptotic gene expression. Thus, the apoptotic gene expression in Mino cells treated IL-21 in mantle cell lymphoma P Gelebart et al with rIL-21 was compared to that of the untreated cells. The results are illustrated in Figure 7 and summarized in Table 1 . Only 6 of the 84 apoptotic genes in the array showed statistically significant differences between the IL-21-treated and the negative controls cells. BIK, NIP3 and HARAKIRI, all of which are proapoptotic BCL-2 family members, were significantly upregulated. The upregulation of BIK, NIP3 and HARAKIRI was confirmed by qRT-PCR (Supplementary Figure 6) and western blots (Figure 7b) . Similarly, the downregulation of BCL-2 and BCL-XL/S was confirmed by qRT-PCR and western blots. The changes in BIK, BCL-2 and BCL-XL/S were further illustrated by densitometic measurements (Figure 7c) . Lastly, as shown in Figure 7d , rIL-21 induced a significant downregulation of secreted TNFa in the culture media, as assessed by ELISA.
The DNA-binding ability of NF-kB was downregulated by rIL-21
We assessed if IL-21-induced apoptosis in MCL involves NF-kB for several reasons. First, STAT1, which is activated in MCL by rIL-21 (as shown above), has been shown to be linked to NF-kB signaling in other cell types. 31 Second, TNFa, an activator of NF-kB, is shown to be downregulated by rIL-21, as described above. Third, NF-kB has been reported to be pathogenetically important for MCL. 4, 7 Using an ELISA-based, commercially available assay kit, we assessed DNA binding by NF-kB extracted from Mino cells treated with rIL-21 or without it. As shown in Figures 8a and b , rIL-21 treatment in MCL significantly induced a significant decrease in DNA binding by NF-kB in both Mino and SP53 cells. Moreover, the downregulation of STAT1 resulted in a significant restoration of the DNA-binding ability of NF-kB. Again, the degree of restoration is not complete, probably related to the fact that our siRNA treatment only resulted in approximately 50% reduction of the STAT1 protein level, as mentioned above.
Discussion
In view of several recent reports that IL-21 has significant biological effects in specific types of B-cell neoplasm, we examined if IL-21 can mediate significant biological effects in MCL. We first demonstrated that MCL cells lines and tumors consistently expressed IL-21R. For the first time, we showed that rIL-21 potently induces apoptosis in MCL cells in vitro. We then explored the molecular mechanism underlying the observed apoptotic response induced by IL-21 in MCL cells. Our studies have revealed the importance of STAT1, a well-described tumor suppressor, in this setting. We also found two other important changes that may contribute to the rIL-21-mediated apoptosis in MCL. The first is related to the decreased DNA binding of NF-kB, which has been previously shown to be important in promoting the survival of MCL cells. 4, 7 Second, we identified significant upregulation of three proapoptotic proteins (BIK, NIP3 and HARAKIRI) and downregulation of two antiapoptotic proteins (BCL-2 and BCL-XL/S). Taken together, IL-21 appears to induce apoptosis in MCL by introducing a 'proapoptotic shift', which is at least partly STAT1 dependent.
Previous studies showed that the biological effects of IL-21 in B cells are dependent on the developmental stage and/or activation status of the cells. For instance, IL-21 induces cell proliferation in human immature B cells 32 but an apoptotic response in mouse mature B cells. 20 More recently, it has been reported that IL-21 induces apoptosis in chronic lymphocytic leukemia and follicular lymphoma 22, 24 but increases cell proliferation in plasma cell myelomas. 25 The mechanism underlying these IL-21-related biological responses in these neoplastic B cells has not been fully studied. Nevertheless, Baker et al. 33 described that IL-21 induces apoptosis in T cells by decreasing BCL-2 expression. This finding echoes our finding that rIL-21 downregulates BCL-2 gene expression in MCL. Gwoda et al. 23 have recently reported that the apoptotic response in chronic lymphocytic leukemia induced by IL-21 is strictly dependent on BIM, although we did not observe any significant change in BIM in our oligonucleotide array studies. We believe that our results shed insight into the mechanisms underlying the biological response induced by IL-21 in lymphoid cells. In this regard, we speculate that the dichotomy of the IL-21 biological effects in B cells may be linked to the fact that lL-21R does not have the death receptor domain. 15, 16 Thus, the biological effects exerted by IL-21, namely apoptosis versus cell proliferation, can be greatly modified during signal transduction. Specifically, IL-21 is known to activate STAT1 and STAT3, well described as a tumor suppressor and an oncoprotein, respectively. 31, 34 We hypothesize that, depending on which of these two signal transducers is preferentially activated, opposite biological effects can be observed. In support of this hypothesis, we identified strong activation of STAT1 IL-21 in mantle cell lymphoma P Gelebart et al IL-21 in mantle cell lymphoma P Gelebart et al 25 Thus, the balance between STAT1 and STAT3 activation may determine the exact biological response exerted by IL-21.
Constitutive NF-kB signaling has been reported to play key roles in the pathogenesis of MCL. [3] [4] [5] Pharmacologic blockade of this signaling pathway has been shown to be effective in killing MCL cells in vitro 4, 7 and treating MCL patients. 14 In keeping with the importance of this transcriptional factor, we found that the IL-21 induces a significant decrease in the DNA binding by NF-kB. Although further studies are needed, we believe that change is likely related to our finding that rIL-21 significant decreases the autocrine production of TNFa, a cytokine known to be activate NF-kB 35 and promote the cell proliferation of MCL cells. 7 In addition, consistent with the concept that the NF-kB signaling is negatively regulated by STAT1 at multiple levels, 31 we found that the downregulation of STAT1 using siRNA partly abrogated the changes in the DNA binding of NF-kB induced by rIL-21 ( Figure 8) .
As mentioned above, we identified that the apoptotic response induced by rIL-21 correlated with a significant upregulation of three proapoptotic members of the BCL-2 family, BIK, 36 NIP3 37 and HARAKIRI. 38 All of these proteins are known to promote apoptosis by interacting with and 0 neutralizing 0 BCL-2. [36] [37] [38] [39] [40] [41] Interestingly, BIK have been described to be mutated in various types of hematopoietic cancers 42 but mutations of this gene have never been found in MCL. 42 Thus, upregulation of BIK, which is probably unmutated and functional in MCL cells, can effectively trigger apoptosis in this cell type. As discussed above, we did not observe an upregulation of BIM, another proapoptotic protein reported to be activated by IL-21 in other cell types. 23, 43, 44 This is likely related to the fact that the BIM gene is often deleted in MCL cell lines and tumors. 45 In this study, we found that IL-21 effectively activates STAT3 in all three MCL cell lines. As discussed above, we speculate that it is the balance between STAT1 activation relative to that of STAT3 dictates the fate of the cells. In this regard, we have examined the expression of phospho-STAT1 in MCL cell lines after long-term treatment. As shown in Figure 4 , rIL-21 not only induced a robust response in activating STAT1 compared to STAT3, STAT1 activation but also appears to be more sustained compared to that of STAT3.
Our data suggests that rIL-21 may be useful therapeutically in MCL. In this regard, rIL-21 is being used in several phase 2 clinical trials for malignant melanoma, renal carcinoma and non-Hodgkin's lymphoma (clinical-trial.gov identifiers NCT00336986, NCT00389285 and NCT00347971). In these trials, the maximum tolerated dose has been determined to be 30 mg/kg. As rIL-21 is given as a bolus, we estimate that the serum peak level in these patients may reach up to a serum level of 500 ng/ml, which is substantially higher that the rIL-21 concentrations used in this study (that is, 10-50 ng/ml) and the normal serum level in humans (that is, 500 pg/ml). IL-21 in mantle cell lymphoma P Gelebart et al
